Initial report on differential expression of sprouty proteins 1 and 2 in human epithelial ovarian cancer cell lines

Journal of Oncology

Volumn , Issue , 2012, Pages

  Moghaddam, Samar Masoumi ^a   Amini, Afshin ^a   Wei, Ai Qun ^a   Pourgholami, Mohammad Hossein ^a   Morris, David Lawson ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; SPROUTY PROTEIN; SPROUTY PROTEIN 1; SPROUTY PROTEIN 2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84871847279     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/373826     Document Type: Article

References (37)

1. Hacohen N., Kramer S., Sutherland D., Hiromi Y., Krasnow M. A., Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell 1998 92 2 253 263 2-s2.0-0032559228 10.1016/S0092-8674(00)80919-8 (Pubitemid 28073048)
2. de Maximy A. A., Nakatake Y., Moncada S., Itoh N., Thiery J. P., Bellusci S., Cloning and expression pattern of a mouse homologue of Drosophila sprouty in the mouse embryo. Mechanisms of Development 1999 81 1-2 213 216 2-s2.0-0032933938 10.1016/S0925-4773(98)00241-X (Pubitemid 29183064)
3. Leeksma O. C., Van Achterberg T. A. E., Tsumura Y., Toshima J., Eldering E., Kroes W. G. M., Mellink C., Spaargaren M., Mizuno K., Pannekoek H., De Vries C. J. M., Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual specificity kinase TESK1. European Journal of Biochemistry 2002 269 10 2546 2556 2-s2.0-0036105451 10.1046/j.1432-1033.2002.02921.x (Pubitemid 34539283)
4. Lo T. L., Yusoff P., Fong C. W., Guo K., McCaw B. J., Phillips W. A., Yang H., Wong E. S. M., Leong H. F., Zeng Q., Putti T. C., Guy G. R., The Ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. Cancer Research 2004 64 17 6127 6136 2-s2.0-4344660712 10.1158/0008-5472.CAN-04- 1207 (Pubitemid 39129413)
5. McKie A. B., Douglas D. A., Olijslagers S., Graham J., Omar M. M., Heer R., Gnanapragasam V. J., Robson C. N., Leung H. Y., Epigenetic inactivation of the human sprouty (hSPRY2) homologue in prostate cancer. Oncogene 2005 24 13 2166 2174 2-s2.0-16444370423 10.1038/sj.onc.1208371 (Pubitemid 40516583)
6. Fritzsche S., Kenzelmann M., Hoffmann M. J., Müller M., Engers R., Gröne H. J., Schulz W. A., Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma. Endocrine-Related Cancer 2006 13 3 839 849 2-s2.0-33751115512 10.1677/erc.1.01190 (Pubitemid 44763260)
7. Wang J., Thompson B., Ren C., Ittmann M., Kwabi-Addo B., Sprouty4, a suppressor of tumor cell motility, is downregulated by DNA methylation in human prostate cancer. Prostate 2006 66 6 613 624 2-s2.0-33645917663 10.1002/pros.20353
8. Fong C. W., Chua M. S., McKie A. B., Ling S. H. M., Mason V., Li R., Yusoff P., Lo T. L., Leung H. Y., So S. K. S., Guy G. R., Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Research 2006 66 4 2048 2058 2-s2.0-33644521213 10.1158/0008-5472.CAN-05-1072
9. Sirivatanauksorn Y., Sirivatanauksorn V., Srisawat C., Khongmanee A., Tongkham C., Differential expression of sprouty genes in hepatocellular carcinoma. Journal of Surgical Oncology 2012 105 3 273 276
10. Feng Y. H., Wu C. L., Tsao C. J., Chang J. G., Lu P. J., Yeh K. T., Uen Y. H., Lee J. C., Shiau A. L., Deregulated expression of sprouty2 and microRNA-21 in human colon cancer: correlation with the clinical stage of the disease. Cancer Biology and Therapy 2011 11 1 111 121 2-s2.0-78751498848 10.4161/cbt.11.1.13965
11. Sutterlüty H., Mayer C. E., Setinek U., Attems J., Ovtcharov S., Mikula M., Mikulits W., Micksche M., Berger W., Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms. Molecular Cancer Research 2007 5 5 509 520 2-s2.0-34250161556 10.1158/1541-7786.MCR-06- 0273 (Pubitemid 46903958)
12. Tennis M. A., Van Scoyk M. M., Freeman S. V., Vandervest K. M., Nemenoff R. A., Winn R. A., Sprouty-4 inhibits transformed cell growth, migration and invasion, and epithelial-mesenchymal transition, and is regulated by Wnt7a through PPAR γ in non-small cell lung cancer. Molecular Cancer Research 2010 8 6 833 843 2-s2.0-77953752993 10.1158/1541-7786.MCR-09-0400
13. Tsavachidou D., Coleman M. L., Athanasiadis G., Li S., Licht J. D., Olson M. F., Weber B. L., SPRY2 is an inhibitor of the Ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant. Cancer Research 2004 64 16 5556 5559 2-s2.0-4143139997 10.1158/0008-5472.CAN-04-1669 (Pubitemid 39095548)
14. Bloethner S., Chen B., Hemminki K., Müller-Berghaus J., Ugurel S., Schadendorf D., Kumar R., Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis 2005 26 7 1224 1232 2-s2.0-22844443766 10.1093/carcin/bgi066 (Pubitemid 41417899)
15. Nielsen T. O., West R. B., Linn S. C., Alter O., Knowling M. A., O'Connell J. X., Zhu S., Fero M., Sherlock G., Pollack J. R., Brown P. O., Botstein D., Van de Rijn M., Molecular characterisation of soft tissue tumours: a gene expression study. The Lancet 2002 359 9314 1301 1307 2-s2.0-0037070754 10.1016/S0140-6736(02)08270-3 (Pubitemid 34310636)
16. Ferlay J., Shin H. R., Bray F., Forman D., Mathers C., Parkin D. M., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2010 127 12 2893 2917 2-s2.0-78049485263 10.1002/ijc.25516
17. Anteby E. Y., Natanson-Yaron S., Greenfield C., Goldman-Wohl D., Haimov-Kochman R., Holzer H., Yagel S., Human placental Hofbauer cells express sprouty proteins: a possible modulating mechanism of villous branching. Placenta 2005 26 6 476 483 2-s2.0-20444414134 10.1016/j.placenta.2004.08.008 (Pubitemid 40796575)
18. Langdon S. P., Lawrie S. S., Establishment of ovarian cancer cell lines. Methods in Molecular Medicine 2001 39 155 159
19. Aletti G. D., Gallenberg M. M., Cliby W. A., Jatoi A., Hartmann L. C., Current management strategies for ovarian cancer. Mayo Clinic Proceedings 2007 82 6 751 770 2-s2.0-34249947772 10.4065/82.6.751 (Pubitemid 46878099)
20. Haimov-Kochman R., Ravhon A., Prus D., Greenfield C., Finci-Yeheskel Z., Goldman-Wohl D. S., Natanson-Yaron S., Reich R., Yagel S., Hurwitz A., Expression and regulation of Sprouty-2 in the granulosa-lutein cells of the corpus luteum. Molecular Human Reproduction 2005 11 8 537 542 2-s2.0-27144478902 10.1093/molehr/gah203 (Pubitemid 41488015)
21. Kwabi-Addo B., Wang J., Erdem H., Vaid A., Castro P., Ayala G., Ittmann M., The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Research 2004 64 14 4728 4735 2-s2.0-3142780658 10.1158/0008-5472.CAN-03-3759 (Pubitemid 38924514)
22. Song K., Gao Q., Zhou J., Qiu S. J., Huang X. W., Wang X. Y., Fan J., Prognostic significance and clinical relevance of Sprouty 2 protein expression in human hepatocellular carcinoma. Hepatobiliary and Pancreatic Diseases International 2012 11 2 177 184
23. Sánchez A., Setién F., Martinez N., Oliva J. L., Herranz M., Fraga M. F., Alaminos M., Esteller M., Rojas J. M., Epigenetic inactivation of the ERK inhibitor Spry2 in B-cell diffuse lymphomas. Oncogene 2008 27 36 4969 4972 2-s2.0-50049125314 10.1038/onc.2008.129
24. Barbáchano A., Ordóňez-Morán P., García J. M., Sánchez A., Pereira F., Larriba M. J., Martínez N., Hernández J., Landolfi S., Bonilla F., Pálmer H. G., Rojas J. M., Mũoz A., SPROUTY-2 and E-cadherin regulate reciprocally and dictate colon cancer cell tumourigenicity. Oncogene 2010 29 34 4800 4813 2-s2.0-77956174563 10.1038/onc.2010.225
25. Velasco A., Pallares J., Santacana M., Gatius S., Fernandez M., Domingo M., Valls J., Yeramian A., Encinas M., Dolcet X., Matias-Guiu X., Promoter hypermethylation and expression of sprouty 2 in endometrial carcinoma. Human Pathology 2011 42 2 185 193 2-s2.0-78751585102 10.1016/j.humpath.2010.08.001
26. Frank M. J., Dawson D. W., Bensinger S. J., Hong J. S., Knosp W. M., Xu L., Balatoni C. E., Allen E. L., Shen R. R., Bar-Sagi D., Martin G. R., Teitell M. A., Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas. Blood 2009 113 11 2478 2487 2-s2.0-63849272814 10.1182/blood-2008-05-156943
27. Lito P., Mets B. D., Kleff S., O'Reilly S., Maher V. M., McCormick J. J., Evidence that sprouty 2 is necessary for sarcoma formation by H-Ras oncogene-transformed human fibroblasts. Journal of Biological Chemistry 2008 283 4 2002 2009 2-s2.0-38349104766 10.1074/jbc.M709046200
28. Schaner M. E., Davidson B., Skrede M., Reich R., Flørenes V. A., Risberg B., Berner A., Goldberg I., Givant-Horwitz V., Tropè C. G., Kristensen G. B., Nesland J. M., Børresen-Dale A. L., Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients. Molecular Cancer 2005 4, article 26 2-s2.0-26844552461 10.1186/1476-4598-4-26 (Pubitemid 41460833)
29. Mason J. M., Morrison D. J., Basson M. A., Licht J. D., Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. Trends in Cell Biology 2006 16 1 45 54 2-s2.0-30444441147 10.1016/j.tcb.2005.11.004 (Pubitemid 43077094)
30. Guy G. R., Jackson R. A., Yusoff P., Chow S. Y., Sprouty proteins: modified modulators, matchmakers or missing links? Journal of Endocrinology 2009 203 2 191 202 2-s2.0-70449445990 10.1677/JOE-09-0110
31. Lee C. C., Putnam A. J., Miranti C. K., Gustafson M., Wang L. M., Vande Woude G. F., Gao C. F., Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis. Oncogene 2004 23 30 5193 5202 2-s2.0-3142736728 10.1038/sj.onc.1207646 (Pubitemid 38980352)
32. Takahashi M., Rhodes D. R., Furge K. A., Kanayama H. O., Kagawa S., Haab B. B., Teh B. T., Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proceedings of the National Academy of Sciences of the United States of America 2001 98 17 9754 9759 2-s2.0-0035859883 10.1073/pnas.171209998 (Pubitemid 32769376)
33. Faratian D., Sims A. H., Mullen P., Kay C., Um I., Langdon S. P., Harrison D. J., Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy. PLoS ONE 2011 6 8 e23772
34. Frolov A., Chahwan S., Ochs M., Arnoletti J. P., Pan Z. Z., Favorova O., Fletcher J., von Mehren M., Eisenberg B., Godwin A. K., Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Molecular cancer therapeutics 2003 2 8 699 709 2-s2.0-0347256705
35. Kim H. J., Bar-Sagi D., Modulation of signalling by sprouty: a developing story. Nature Reviews Molecular Cell Biology 2004 5 6 441 450 2-s2.0-2942568167 10.1038/nrm1400 (Pubitemid 38745494)
36. Hausott B., Vallant N., Auer M., Yang L., Dai F., Brand-Saberi B., Klimaschewski L., Sprouty2 down-regulation promotes axon growth by adult sensory neurons. Molecular and Cellular Neuroscience 2009 42 4 328 340 2-s2.0-70350749418 10.1016/j.mcn.2009.08.005
37. Impagnatiello M. A., Weitzer S., Gannon G., Compagni A., Cotten M., Christofori G., Mammalian sprouty-1 and -2 are membrane-anchored phosphoprotein inhibitors of growth factor signaling in endothelial cells. Journal of Cell Biology 2001 152 5 1087 1098 2-s2.0-0035809919 10.1083/jcb.152.5.1087 (Pubitemid 34286083)